Amgen Inc. logo

Amgen Inc. (AMGN)

Market Closed
16 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS)
$
432. 49
-1.54
-0.3548%
$
223.91B Market Cap
19.61 P/E Ratio
0.07% Div Yield
2.56M Volume
18.58 Eps
$ 434.03
Previous Close
Add Transaction
Day Range
431.43 438.82
Year Range
288 447.03
Want to track AMGN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Amgen (AMGN) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Amgen (AMGN) Rises Yet Lags Behind Market: Some Facts Worth Knowing

In the latest trading session, Amgen (AMGN) closed at $272.11, marking a +0.99% move from the previous day.

Zacks | 1 year ago
US FDA approves Amgen's colorectal cancer therapy

US FDA approves Amgen's colorectal cancer therapy

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.

Reuters | 1 year ago
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows

2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while -- is one of the best formulas for earning terrific returns.

Fool | 1 year ago
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know

In the most recent trading session, Amgen (AMGN) closed at $267.10, indicating a -1.14% shift from the previous trading day.

Zacks | 1 year ago
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term

Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 1 year ago
Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)

Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)

Amgen Inc. (NASDAQ:AMGN ) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 13, 2025 6:00 PM ET Company Participants Robert Bradway - Chairman, CEO & President Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody.

Seekingalpha | 1 year ago
Why Amgen (AMGN) is a Top Value Stock for the Long-Term

Why Amgen (AMGN) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
Amgen (AMGN) Advances While Market Declines: Some Information for Investors

Amgen (AMGN) Advances While Market Declines: Some Information for Investors

Amgen (AMGN) closed at $262.05 in the latest trading session, marking a +1.34% move from the prior day.

Zacks | 1 year ago
Amgen (AMGN) Stock Sinks As Market Gains: Here's Why

Amgen (AMGN) Stock Sinks As Market Gains: Here's Why

Amgen (AMGN) concluded the recent trading session at $258.59, signifying a -1.01% move from its prior day's close.

Zacks | 1 year ago
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?

Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?

Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 1 year ago
Amgen: The Buying Opportunity Has Now Arrived (Rating Upgrade)

Amgen: The Buying Opportunity Has Now Arrived (Rating Upgrade)

Since my previous article, shares of Amgen meaningfully lagged the S&P 500 index. The company's revenue and non-GAAP EPS climbed higher in the third quarter. Amgen's deleveraging efforts are progressing, and the company is on pace to return to its pre-Horizon capital structure by the end of 2025.

Seekingalpha | 1 year ago
Loading...
Load More